electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place on Wednesday, November 11, 2026, at The Westin New York Grand Central in New York City.
Joshua Lev, Co-Chief Executive Officer, President and Chief Financial Officer, will present at the conference and host one-on-one meetings with investors throughout the day.
Investors interested in scheduling a one-on-one meeting should contact their Canaccord Genuity sales representative.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
